Skip to main content
Premium Trial:

Request an Annual Quote

SNP Genotyping NIH launches genotype programs; Affy, Pfizer contribute


Only six weeks into the year, the National Institutes of Health and its parent agency, the Department of Health and Human Services, announced the creation of two related research initiatives to accelerate research on the genetic roots of common diseases. Funding for one will come out of the coffers of the US President’s budget, while the other is set to receive financial pledges from Affymetrix and Pfizer.

The Genes and Environment Initiative, championed by HHS Secretary Mike Leavitt and set to receive $68 million from the FY 2007 budget, aims to elucidate the causal interplay between common diseases, genes, and environmental cues. If approved by Congress, GEI’s funding will commence in 2007 and continue for several years.

GEI will marry technology development and genotyping studies in an effort to evaluate how cues in the environment interact with specific genotypes to cause disease. “Given the recent advances in biomedical research, this is the right time to take on this challenge,” says David Schwartz, part of GEI’s coordinating committee. Of the project’s proposed first-year funding, $26 million will go to genetic analysis and $14 million will funnel into the development of new environmental monitoring tools.

The three-year Genetic Association Information Network brings together Pfizer, Affymetrix, and the Foundation for the National Institutes of Health in a public-private partnership that will employ whole-genome association studies to uncover genetic contributions to seven common diseases. Pfizer will provide genotyping services through its partnership with Perlegen Sciences.

The Foundation for NIH will manage this initiative with help from NIH and Pfizer scientists, as well as other experts. Pfizer has committed $5 million to setting up the network, and it promises $15 million more to support lab studies of the first five diseases. Affymetrix is set to contribute about $6 million more to characterize two more diseases. Altogether, the GAIN partnership hopes to corral $60 million in private funding for additional studies and welcomes interested partners in industry.

Elias Zerhouni estimates that an investment of $3 million to $6 million will be needed for the first stage of genotyping for each study cohort of 1,000 to 2,000 patients. Investigators and research centers are invited to submit applications to have free genotyping performed on extant samples from patients with specific diseases in case-control studies.

The National Center for Biotechnology Information at the National Library of Medicine will be custodian of the resulting data, making it available to qualified investigators in a public domain database that has been beta-tested to handle a diverse array of information. All quality-control tested genotyping data will be available through the SNP Database.

Other GAIN participants include Abbott Laboratories as well as the National Human Genome Research Institute and several other NIH centers. A peer review committee and technical advisory board are in place to provide additional scientific oversight of the project.

— Jen Crebs

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.